New drug ABBV-722 put through interaction tests in healthy volunteers
NCT ID NCT07567781
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing whether a new drug called ABBV-722 changes how the body processes several common medications. Twelve healthy adults will take ABBV-722 along with a 'cocktail' of other drugs (midazolam, digoxin, pitavastatin, metformin, and sitagliptin) to see if their levels in the blood are affected. The main goal is to check for side effects and measure drug concentrations, helping to guide future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-722
What this could lead to
If successful, this study will help doctors understand how ABBV-722 interacts with other medications, guiding safe dosing in future trials.
What could go wrong
This is a very early, small study in healthy volunteers, not patients. It only measures drug levels and safety, not whether ABBV-722 works for any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acpru /Id# 282184
RECRUITINGGrayslake, Illinois, 60030, United States